Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID

202195 citationsJournal Articlebronze Open Access

Authors

Kimberly N. Weaver · University of North Carolina at Chapel Hill

Xian Zhang · University of North Carolina at Chapel Hill

Xiangfeng Dai · University of North Carolina at Chapel Hill

Runa Watkins · University of Maryland, Baltimore

Jeremy Adler · University of Michigan

Marla C. Dubinsky · Icahn School of Medicine at Mount Sinai

Arthur Kastl

Abstract

Our findings provide reassurance that the severe acute respiratory syndrome coronavirus 2 vaccine is safe and well tolerated among individuals with IBD, which may help to combat vaccine hesitancy and increase vaccine confidence.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Inflammatory Bowel Disease COVID-19 Clinical Research Studies

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Inflammatory Bowel Diseases

Volume 28, Issue 10, pp. 1497-1505

DOI: 10.1093/ibd/izab302

Field-Weighted Citation Impact: 5.40

Command Palette